Drug Insights

Is Durlobactam/Sulbactam approved by the FDA?

2 August 2024
3 min read

Yes, durlobactam/sulbactam, marketed under the brand name Xacduro, is FDA approved. The approval was granted on May 23, 2023.

What is Durlobactam/Sulbactam?

Durlobactam/sulbactam is a combination antibiotic used to treat pneumonia, specifically hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex. It is intended for use in adults and is administered intravenously.

Usage and Dosage

  • Dosage Form: Intravenous powder for reconstitution (0.5 g-1 g (1 g-1 g dose))
  • Drug Class: Beta-lactamase inhibitors
  • Administration: Given as an infusion into a vein by a healthcare provider. The usual adult dose for nosocomial pneumonia is 1 g of durlobactam and 1 g of sulbactam every 6 hours, for a duration of 7 to 14 days. The exact duration is determined based on the patient's clinical status and kidney function.

Side Effects

Common side effects of durlobactam/sulbactam may include:

  • Low blood levels of potassium
  • Diarrhea
  • Abnormal liver function tests
  • Anemia (low red blood cells)

Serious side effects that require immediate medical attention include:

  • Severe stomach pain
  • Diarrhea that is watery or bloody (even if it occurs months after the last dose)
  • Signs of an allergic reaction: hives, difficult breathing, swelling of the face, lips, tongue, or throat

Warnings and Precautions

  • Medical History: Inform your doctor if you have any allergies, especially to antibiotics such as meropenem, cephalexin, cefdinir, amoxicillin, ampicillin, penicillin, or others.
  • Infections and Diarrhea: Antibiotic medicines can cause diarrhea. Notify your healthcare provider if you experience watery or bloody diarrhea.
  • Pregnancy and Breastfeeding: Discuss with your doctor if you are pregnant or breastfeeding.
  • Age Restriction: Not approved for use in individuals younger than 18 years old.

Treatment Considerations

  • Missed Dose: In a medical setting, missing a dose is unlikely. However, if it happens, the medical team will manage it appropriately.
  • Overdose: In a medical setting, an overdose would be treated quickly.
  • Activity Restrictions: Follow your doctor's instructions about any restrictions on food, beverages, or activities.

Drug Interactions

  • Interactions: Inform your doctor about all the medications you are taking, including prescription and over-the-counter medicines, vitamins, and herbal products. Notable interactions include probenecid, which can affect the efficacy and side effects of durlobactam/sulbactam.

Conclusion

Durlobactam/sulbactam (Xacduro) is an FDA-approved treatment for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by specific bacteria. The approval on May 23, 2023, marks its availability for managing these serious infections, particularly in healthcare settings. As with any antibiotic treatment, it is crucial to follow medical advice and report any adverse effects promptly to ensure safe and effective use.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Formycon initiates Phase III clinical trial for Keytruda® biosimilar candidate FYB206
Latest Hotspot
3 min read
Formycon initiates Phase III clinical trial for Keytruda® biosimilar candidate FYB206
2 August 2024
Formycon AG announced the first enrollment in the Phase III "Lotus" study comparing FYB206/pembrolizumab with leading cancer drug Keytruda for safety and efficacy.
Read →
Is Epcoritamab approved by the FDA?
Drug Insights
4 min read
Is Epcoritamab approved by the FDA?
2 August 2024
Yes, epcoritamab, marketed under the brand name Epkinly, is FDA approved. It received approval on May 19, 2023.
Read →
Celldex Reports Successful Phase 2 Results for Barzolvolimab in Chronic Inducible Urticaria
Latest Hotspot
2 min read
Celldex Reports Successful Phase 2 Results for Barzolvolimab in Chronic Inducible Urticaria
2 August 2024
Celldex Therapeutics announces successful findings from Phase 2 trial of Barzolvolimab for chronic inducible urticaria.
Read →
Is Beremagene geperpavec approved by the FDA?
Drug Insights
3 min read
Is Beremagene geperpavec approved by the FDA?
2 August 2024
Beremagene geperpavec topical, marketed under the brand name Vyjuvek, is an FDA-approved medication for treating wounds caused by dystrophic epidermolysis bullosa (DEB).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.